All lobbying filings

A Ascension

Ascension Health Alliance D/B/A Ascension filed a Q1 report for Ascension Health Alliance D/B/A Ascension on April 19, 2026.

Lobbying for Ascension Health Alliance D/B/A Ascension

As filed: ASCENSION HEALTH ALLIANCE D/B/A ASCENSION for ASCENSION HEALTH ALLIANCE D/B/A ASCENSION.

All filings by Ascension Health Alliance D/B/A Ascension · Everything Ascension Health Alliance D/B/A Ascension has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 19, 2026

Expenses

$690,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 5

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 5

Pharmacy

340B Program; Issues related to affordable prescription drugs; Equitable Community Access to Pharmacy Services Act; issues related to preventing and mitigating drug shortages;

Budget/Appropriations

H.R. 1, the One Big Beautiful Bill Act; EAPTC Extension

Taxation/Internal Revenue Code

H.R. 247/S. 46, the Healthcare Affordability Act; extending advanced premium tax credits (APTCs); issues related to provider taxes.

Health Issues

Labor Health and Human Services Education, Homeland, Commerce, Justice, Science Appropriations; 340B Program; Issues related to affordable prescription drugs; Issues related to health care workforce and staffing; Issues related to health care privacy; Issues related to telehealth authorities; Issues related to hospital price transparency; Issues related to hospital reimbursement; Issues related to nonprofit hospital practices; Site-neutral payment policy; Issues related to hospital outpatient department payments; Issues related to DSH; Issues related to Medicaid supplemental payments; Issues related to Medicare payments; Issues related to Medicare Advantage reimbursement and prior authorization; Issues related to childrens medical care; issues related to rural health; Issues related to mental and behavioral health; enhanced Advanced Premium Tax Credits; issues related to the implementation of H.R. 1, the One Big Beautiful Bill Act;

Medicare/Medicaid

Labor Health and Human Services Education, Homeland, Commerce, Justice, Science Appropriations; 340B Program; Issues related to affordable prescription drugs; Issues related to health care workforce and staffing; Issues related to health care privacy; Issues related to telehealth authorities; Issues related to hospital price transparency; Issues related to hospital reimbursement; Issues related to nonprofit hospital practices; Site-neutral payment policy; Issues related to hospital outpatient department payments; Issues related to DSH; Issues related to Medicaid supplemental payments;Issues related to Medicare payments; Issues related to Medicare Advantage reimbursement and prior authorization; Issues related to childrens medical care; issues related to rural health; Issues related to mental and behavioral health; enhanced Advanced Premium Tax Credits; issues related to the implementation of H.R. 1, the One Big Beautiful Bill Act;

Bills named in this filing 3

H.R. 1
One Big Beautiful Bill Act
H.R. 247
Health Care Affordability Act of 2025
S. 46
Health Care Affordability Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.